Do you know about the Future Fund: Breakthrough programme? It's a £425m UK-wide programme which encourages private investors to co-invest in high-growth, innovative firms. Find out more: https://bit.ly/3jF3lY8 #FFBreakthrough
British Patient Capital
Financial Services
Sheffield, England 5,757 followers
Our mission is to enable long-term investment in innovative companies across the UK led by ambitious entrepreneurs
About us
Our mission is to enable long-term investment in innovative companies across the UK led by ambitious entrepreneurs. The UK provides a fertile ground for innovation to thrive, but a lack of access to patient capital continues to hold back some UK companies from scaling up and fulfilling their commercial potential. British Patient Capital will enable greater availability of this type of long-term finance and will help build the UK’s innovation economy. British Patient Capital will be developed as a separate subsidiary of the British Business Bank and builds on a successful 10-year heritage of investing £1bn into UK venture and growth capital.
- Website
-
https://www.britishpatientcapital.co.uk/
External link for British Patient Capital
- Industry
- Financial Services
- Company size
- 11-50 employees
- Headquarters
- Sheffield, England
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
West Street
Sheffield, England, GB
-
Salisbury Square
London, England EC4Y 8, GB
Employees at British Patient Capital
-
Hazel Moore
Chairman of FirstCapital - smarter dealmaking for growth tech companies
-
Manu Gupta
Founder @ Blue Lion VC; prev. Founding Team @ Lakestar (>$1.4bn AUM)
-
Arnaud Garcon
Senior Investment Manager Life Sciences
-
Kerry Baldwin
Managing Partner, Co-founder IQ Capital Deeptech VC, Past Chair British Private Equity and Venture Capital Association 2021/22
Updates
-
Pension funds in the US contribute 70 per cent of VC investment, according to data from the British Business Bank, versus just a 10th in the UK. We're playing a "catalytic role" in changing that. https://lnkd.in/edUaq-xz
-
As the UK’s largest domestic investor in UK venture and venture growth opportunities, we are increasing access to, and the availability of, long-term, patient finance. We do this via three schemes, each one addressing specific market issues ⤵️ https://bit.ly/46AnNw8
-
#FridayInspiration Against the backdrop of stereotypes, women in VC leadership aren't just challenging norms but reshaping them. Gender isn't a barrier; it's a catalyst for innovation and growth, says Dr. Rabab Nasrallah of Earlybird Venture Capital 🌍💪 #VentureCapital #WomenInSTEM #DiversityMatters
-
“In the UK we’re good at starting companies but not so good at scaling them up. We would like to see more home-grown, fully-funded champions.” Our Board Director Ian Connatty spoke to ICAS - The Professional Body of CAs magazine about our mission to support high-growth companies with patient capital and put a spotlight on the inspiring success stories in our portfolio.
Seeds of success
camagazine.icas.com
-
Accurx is a healthcare communications specialist joining up care between healthcare professionals and with their patients. Since raising a Series A funding round led by @atomico in 2019, they’ve delivered communications to over 54 million patients.
-
Congratulations to Micriobiotica on starting their clinical trials, which is a significant milestone in the development of treatments for patients. We invested in Microbiotica’s £50m Series B funding round in 2022. Find out more about the clinical trials 👇
We’re delighted to announce we have received regulatory approvals in the EU and UK to initiate Phase 1b clinical studies for our live biotherapeutic products (LBPs) in advanced melanoma (🎶MELODY-1: MB097) and ulcerative colitis (🎼COMPOSER-1: MB310)! MB097 consists of a defined consortium of nine bacterial strains, designed to enhance the efficacy of immune checkpoint inhibitors like KEYTRUDA®. MB310 is a defined microbial consortium identified from healthy donors with mechanisms promoting gut healing and immune regulation. This milestone marks the start of our transition to a clinical-stage company, bringing us closer to transforming patient care in immuno-oncology and inflammatory bowel disease through precision microbiome medicines. With additional financing secured, we're well-funded to advance these programmes to critical readout and anticipate sharing initial data by the end of 2025. 👏A huge thank you to our investors, incredible team and collaborators for making this major milestone possible! 🔗Read our press release: https://lnkd.in/esWjmm_4 🔬www.microbiotica.com #Biotech #Innovation #Microbiome #clinicalstudies #melanoma #ulcerativecolitis
-
Xampla is making an impact on combating plastic pollution. Funding from our partners Amadeus Capital Partners enabled this Cambridge-based company to develop the world’s first commercial plant based alternative to plastic packaging ♻️ #CleanTech #PlasticFree
-
Pension funds in the US contribute 70 per cent of VC investment, according to data from the British Business Bank, versus just a 10th in the UK. We're playing a "catalytic role" in changing that. New from Financial Times: https://lnkd.in/edUaq-xz
European VCs’ reliance on governments is not all bad
ft.com
-
#ICYMI: We've committed a total $90m across Balderton Capital's latest funds: Balderton IX and Balderton Growth II. The funds will back high-growth technology companies across the UK and Europe at both the early and venture growth stages. Read more via UKTN 👇
Revolut backer Balderton Capital raises £1bn across two funds
https://www.uktech.news